Tibolone
is a synthetic
steroid hormone drug, which is fairly non-selective in its binding profile, acting as an
agonist at all five of the Type I
steroid hormone receptors. It has also been investigated as a possible treatment for
female sexual dysfunction, although it is unclear whether the benefits in this application justify the known risks of the drug.
A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen, raloxifene, and tibolone used to treat breast cancer significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects.
